A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Otsuka logo

Otsuka

Status and phase

Enrolling
Phase 3

Conditions

Autosomal Recessive Polycystic Kidney (ARPKD)

Treatments

Drug: Tolvaptan Suspension
Drug: Tolvaptan Tablets

Study type

Interventional

Funder types

Industry

Identifiers

NCT04782258
2020-005992-10 (EudraCT Number)
156-201-00307

Details and patient eligibility

About

The primary objective of this study is to evaluate the safety of tolvaptan in pediatric subjects with autosomal recessive polycystic kidney disease (ARPKD)

Full description

This study is a multinational, multicenter, open-label, non-randomized trial. The study consist of three periods: Screening Period, Treatment period and Follow-up period. Tolvaptan has been demonstrated to delay the decline of kidney function in adults with rapidly progressing ADPKD (CKD stages 1 to 4), a closely related indication to ARPKD, as measured by estimated glomerular filtration rate (eGFR) and Total Kidney Volume (TKV). Participants in this study will be assigned to tolvaptan and followed for 18 months over the course of the study. The overall trial duration is expected to be approximately 3.5 years.

Enrollment

10 estimated patients

Sex

All

Ages

28 days to 18 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female subjects between 28 days and less than 18 years of age, with clinical features that are consistent with a diagnosis of ARPKD.
  • Ability for parent/legal guardian to provide written, informed consent prior to initiation of any trial-related procedures, and ability, in the opinion of the principal investigator, to comply with all the requirements of the trial. Ability to provide written informed assent from all subjects old enough per local laws to provide assent.

Exclusion criteria

  • Premature birth (≤ 32 weeks gestational age) for infants 28 days to < 12 weeks of age.
  • Anuria or RRT defined as intermittent or continuous hemodialysis, peritoneal dialysis, hemofiltration, hemodiafiltration or history of kidney transplantation.
  • Evidence of syndromic conditions associated with renal cysts (other than ARPKD).
  • Abnormal liver function tests including ALT and AST, > 1.2 × ULN (upper limit of normal).
  • Has splenomegaly or portal hypertension (HTN).
  • Parents with renal cystic disease.
  • Receiving chronic diuretic that could not be adjusted after tolvaptan initiation.
  • Cannot be monitored for fluid balance.
  • Has or at risk of having sodium and potassium electrolyte imbalances, as determined by the investigator.
  • Has or at risk of having significant hypovolemia as determined by investigator.
  • Clinically significant anemia, as determined by investigator.
  • Platelets < 50000 µL.
  • Severe systolic dysfunction defined as ejection fraction < 14%.
  • Serum sodium levels < 130 mmol/L or >145 mmol/L.
  • Taking any other experimental medications.
  • Require ventilator support.
  • Taking medications known to induce CYP3A4 (CYP = Cytochrome P).
  • Having an infection including viral that would require therapy disruptive to IMP dosing.
  • Females who are breast-feeding or who have a positive pregnancy test result prior to receiving IMP.
  • Subjects with a history of substance abuse (within the last 6 months).
  • Subjects who have bladder dysfunction and/or difficulty voiding.
  • Subjects taking a vasopressin agonist (eg, desmopressin).
  • Subjects with a history of persistent noncompliance with antihypertensive or other important medical therapy.
  • Subjects taking medications or having concomitant illnesses likely to confound endpoint assessments, including taking approved (ie, marketed) therapies for the purpose of affecting PKD cysts such as tolvaptan, vasopressin antagonists, anti-sense ribonucleic acid (RNA) therapies, rapamycin, sirolimus, everolimus, or somatostatin analogs (ie, octreotide, sandostatin).
  • Received or are scheduled to receive a liver transplant.
  • History of cholangitis within the last 6 months.
  • Has findings consistent with clinically significant portal hypertension (eg, varices, variceal bleeding, hypersplenism indicated by thrombocytopenia).

Trial design

Primary purpose

Treatment

Allocation

Non-Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

10 participants in 2 patient groups

Tolvaptan Suspension
Experimental group
Description:
Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age. Treatment duration is 18 months.
Treatment:
Drug: Tolvaptan Suspension
Tolvaptan Tablets
Experimental group
Description:
Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets. Treatment duration is 18 months.
Treatment:
Drug: Tolvaptan Tablets

Trial contacts and locations

19

Loading...

Central trial contact

Leslyn Hermonstine; Linda Cappiello

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems